- CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemiaZhao, Ze An; Jiang, Yu; Chen, Yan-yu; Wu, Ting; Lan, Qun-sheng; Li, Yong-mei; Li, Lu; Yang, Yang; Lin, Cui-ting; Cao, Ying; Zhou, Ping-zheng; Guo, Jia-yin*; Tian, Yuan-xin*; Pang, Jian-xin*Acta Pharmacologica Sinica, 2022, 43(1): 121-132.被引 15
- Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemiaZhao, Zean; Liu, Jin; Kuang, Peihua; Luo, Jian; Surineni, Goverdhan; Cen, Xiaolin; Wu, Ting; Cao, Ying; Zhou, Pingzheng; Pang, Jianxin*; Zhang, Qun*; Chen, Jianjun*European Journal of Medicinal Chemistry, 2022, 229: 114092.被引 9
- THE ASSOCIATION BETWEEN THE LEVELS OF URIC ACID AND RENAL OUTCOMES IN EARLY CKD PATIENTS: A MULTI-CENTER REAL-WORLD DATA ANALYSISLuo, Yuxin; Song, Qirong; Fu, Sha; Liu, Qin; Chen, Xiaohong; Nie, Sheng; Chen, Junzhe; Tang, Ying60th ERA Congress, Milan, ITALY, 2023-06-15 To 2023-06-18.
期刊论文
CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia (vol 43, pg 121, 2022)
22阅读
